Stockscreener 앱 받기
11.32
2.25%
-0.26
시간 외 거래:
11.11
-0.21
-1.86%
전일 마감가:
$11.58
열려 있는:
$11.7
하루 거래량:
1.88M
Relative Volume:
0.80
시가총액:
$1.12B
수익:
-
순이익/손실:
$-44.84M
주가수익비율:
-24.09
EPS:
-0.47
순현금흐름:
$-44.23M
1주 성능:
+9.80%
1개월 성능:
+7.81%
6개월 성능:
-14.50%
1년 성능:
-18.62%
1일 변동 폭
$11.00
$11.70
1주일 범위
$10.00
$11.70
52주 변동 폭
$9.335
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
명칭
Ars Pharmaceuticals Inc
전화
858-771-9307
주소
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
SPRY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
11.32 | 1.14B | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-04 | 개시 | Roth Capital | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-10 | 개시 | Oppenheimer | Outperform |
| 2024-08-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | 재확인 | Leerink Partners | Outperform |
| 2024-07-25 | 개시 | Raymond James | Outperform |
| 2024-03-05 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | 개시 | Wedbush | Outperform |
| 2023-01-03 | 개시 | William Blair | Outperform |
| 2022-12-13 | 개시 | SVB Leerink | Outperform |
모두보기
Ars Pharmaceuticals Inc 주식(SPRY)의 최신 뉴스
Pattern recognition hints at ARS Pharmaceuticals Inc. upside2025 Price Momentum & Long-Term Safe Return Strategies - newser.com
Firm Helps Secure Favorable Decision from European Patent Office on Behalf of ARS Pharmaceuticals - Wilson Sonsini
ARS Pharmaceuticals' (SPRY) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy - MarketScreener
Asthma Market to Evolve Rapidly Over the Next Decade by 2034, - openPR.com
Firm Advises ARS Pharma on Patent Matters Related to Loan Facility Up to $250 Million - Wilson Sonsini
ARS Pharmaceuticals Forms Death Cross, Signaling Bearish Trend Ahead - Markets Mojo
ARS Pharma’s epinephrine nasal spray patent upheld in Europe - Investing.com
ARS Pharmaceuticals receives favorable decision from European Patent Office on patent related to neffy (epinephrine nasal spray) - MarketScreener
ARS Pharmaceuticals Receives Favorable Decision from - GlobeNewswire
EP 3678649 Upheld in 30+ Countries: ARS Pharmaceuticals' neffy® patent Secured Through 2039 - Stock Titan
Knights of Columbus Asset Advisors LLC Boosts Stock Position in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
What drives ARS Pharmaceuticals Inc stock priceEmerging Market Stocks & Your Free Entry to Smart Investing Starts Here - earlytimes.in
ARS Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Is ARS Pharmaceuticals Inc. building a consolidation baseWeekly Market Report & Safe Entry Point Identification - newser.com
Using data tools to time your ARS Pharmaceuticals Inc. exit2025 Investor Takeaways & Technical Buy Zone Confirmation - newser.com
How to use Fibonacci retracement on ARS Pharmaceuticals Inc.M&A Rumor & Real-Time Sentiment Analysis - newser.com
Published on: 2025-10-05 03:09:06 - newser.com
Is ARS Pharmaceuticals Inc. stock a buy before product launchesWeekly Trade Recap & Breakout Confirmation Alerts - newser.com
A Look at ARS Pharmaceuticals’s Valuation Following Major $250M Funding for Neffy Commercial Growth - Sahm
ARS Pharmaceuticals (SPRY) Is Up 5.2% After Securing $250M Term Loan to Accelerate Neffy Launch – Has the Bull Case Changed? - Yahoo Finance
Why ARS Pharmaceuticals (SPRY) Is Up 7.8% After Securing $250M Loan and Japan Approval for neffy - Sahm
William Blair Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating - 富途牛牛
ARS Pharma secures $250M loan to accelerate Neffy rollout - MSN
William Blair Expects Lower Earnings for ARS Pharmaceuticals - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) Trading Up 6.6%Here's Why - MarketBeat
Epinephrine nasal spray maker ARS sues Aptar alleging device supply monopoly - Reuters
RA Capital Management Funds Expansion of ARS Pharma Commercial Activity - citybiz
RA Capital Management Funds Expansion of ARS Pharma Commercial Activity, Expands Portfolio of Financing Solutions for Innovative Healthcare Companies - WV News
ARS Pharmaceuticals Secures $250 Million Credit Agreement - MSN
ARS Pharma secures $100 million loan to accelerate neffy growth By Investing.com - Investing.com Nigeria
ARS Pharmaceuticals outlines 2025 growth strategy with neffy commercialization and global expansion - MSN
ARS Pharmaceuticals Locks In $250 Million To Grow Neffy - Finimize
ARS Pharma secures $100 million loan to accelerate neffy growth - Investing.com India
ARS Pharmaceuticals Secures Up to $250 Million Loan - GlobeNewswire
ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy® - Yahoo Finance
ARS Pharmaceuticals, Inc. announced that it expects to receive $250 million in funding - MarketScreener
ARS Pharmaceuticals Hits 52-Week Low at $9.34 Amid Financial Struggles - Markets Mojo
ARS Pharmaceuticals stock maintains Strong Buy rating at Raymond James By Investing.com - Investing.com Canada
ARS Pharmaceuticals stock maintains Strong Buy rating at Raymond James - Investing.com India
ARS Pharmaceuticals (NASDAQ:SPRY) Reaches New 52-Week LowWhat's Next? - MarketBeat
Ars Pharmaceuticals Inc (SPRY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Ars Pharmaceuticals Inc 주식 (SPRY) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Scott Kathleen D. | Chief Financial Officer |
Aug 21 '25 |
Option Exercise |
1.50 |
12,500 |
18,750 |
22,542 |
| Scott Kathleen D. | Chief Financial Officer |
Aug 21 '25 |
Sale |
15.00 |
12,500 |
187,500 |
10,042 |
| Tanimoto Sarina | CHIEF MEDICAL OFFICER |
Aug 20 '25 |
Sale |
14.09 |
37,656 |
530,626 |
1,247,447 |
| Tanimoto Sarina | CHIEF MEDICAL OFFICER |
Aug 19 '25 |
Sale |
14.03 |
12,344 |
173,130 |
1,285,103 |
5.74%
자본화:
|
볼륨(24시간):